Point Roberts, WA. - April 14, 2011 – Investorideas.com, a leader in sector stock research presents a new interview in its series of biotech Q&A's, featuring Jim Joyce, CEO of Aethlon Medical (OTCBB: AEMD).
The Hemopurifier® from Aethlon Medical is a first-in-class medical device candidate to treat infectious disease. Human studies have documented that the Hemopurifier® can significantly reduce viral load in Hepatitis-C virus (HCV) and Human Immunodeficiency Virus (HIV) infected patients in the absence of antiviral drugs. A study is currently underway to demonstrate the benefit of the Hemopurifier® as an adjunct to HCV drug therapy. Additional details can be accessed online at www.aethlonmedical.com
InvestorIdeas: How does your Hemopurifier® differ from drug therapies to treat infectious disease?
Mr. Joyce: Well, our approach is a complete departure from the consensus approach of introducing drug agents into the body to inhibit viral replication. As you are likely aware, these agents can have countering side effects or mechanisms of action that may not be fully understood. So, instead of adding agents into the body, our Hemopurifier® subtracts or removes viruses and other harmful particles from circulation without drug-related side effects. We think our therapeutic filtration approach could redefine the premise of how to treat infectious disease and we believe our strategy is far more innovative than another me-too drug inhibitor.
InvestorIdeas: Is a device that removes harmful particles from the body really considered to be innovative?
Mr. Joyce: The idea of a therapeutic filtration device that can remove harmful particles from circulation is not original. The basis of kidney dialysis, which keeps individuals with renal disease alive, is based on therapeutic filtration. However, like dialysis, previous therapeutic filtration strategies have sought to remove particles from circulation by molecule size, which is an indiscriminate approach that can also remove elements from circulation that are required for health. This factor has primarily limited the use of therapeutic filtration to niche markets. Our Hemopurifier® is truly innovative in the sense that we discriminate to selectively remove infectious viruses and other harmful particles from the entire circulatory system. It is this advancement that allows us to pursue opportunities in the much larger infectious disease and cancer markets.
InvestorIdeas: So it would seem your Hemopurifier® is positioned as a competitor to drug therapies.
Mr. Joyce: That is certainly not our intent. In fact, we expect to be an ally to the drug industry for several compelling reasons. First, if you really want to enhance or extend the benefit of drug therapies, you remove the strains of viruses that are causing drugs to fail and you do it without adding drug toxicity or interaction risks. But to fully unlock the capability of drug therapies you need to provide other complementary mechanisms that are beyond the reach of drugs. In that regard, we provide a strategy to address the toxins shed from viral surfaces to kill immune cells and particles known as exosomes that allow viruses to transport other disease-enhancing particles below the surveillance of the immune system. So our device in combination with drug therapy would seem to be a win-win scenario.
InvestorIdeas: What if a virus is not treatable with drug therapy?
Mr. Joyce: In reality, a vast majority of the viruses that are known to be infectious to man are not treatable with drugs. In scenarios that are life threatening, our Hemopurifer® is likely to be the sole strategy to address viral infections that are not treatable with drugs. For this reason, our Hemopurifier® is immensely valuable as new viruses like the coronavirus underlying the SARS outbreak of 2003 will emerge naturally in the future. We also face the looming threat of biological weapons purposely designed to defeat drug therapies. In either case, our Hemopurifier® provides a decision free first response that can augment the body's own immune response to such exposures, which is certainly more logical than an post-exposure strategy comprised of first identifying the virus that is killing people, and then establishing post-death research programs that may or may not yield a viable treatment candidate years after the fact.
Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the company's ability to commercialize its Hemopurifier® in India, capability of the Hemopurifier® to reduce viral loads and other disease conditions or to identify or treat disease conditions such as cancer or Hepatitis-C, including the ability to capture exosomes and the impact that potential ability may have on disease conditions, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the sale of its products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.
Disclaimer / Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. AETHLON MEDICAL INC (OTC BB: AEMD) Showcase biotech, biodefense and defense stock on Investorideas.com ($one thousand five hundred per month, $five thousand per month in 144 stock) Effective March 15, 2011
Published at the Investorideas.com Newswire - Big ideas for Global Investors
Disclaimer/ Disclosure:The Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.